Catalog packs exist for repeated, well-specified laboratory needs. They fail — quietly — when the experiment needs a sequence, modification, scale, presentation, or analytical package that is not on the shelf. Custom peptide synthesis is the qualification pathway for those cases: a written scientific requirement in, documented material and records out.
This article explains when to leave the catalog, what a laboratory RFQ should contain, and how Simple Life Sciences structures intake through closeout. It is not a price list, not a lead-time guarantee, and not a shopping comparison against other storefronts. Projects described here are research use only (RUO): for qualified non-clinical laboratory investigation, not for human or animal administration, diagnosis, treatment, compounding, clinical use, or consumer products.
When a catalog SKU is the wrong tool
A stock item is the wrong tool when the lab needs a defined sequence or analog that is not offered as a controlled catalog material; when termini, labels, non-natural residues, cyclization, or conjugation change the synthesis problem; when scale, purification target, or named analytics exceed a generic catalog card; or when presentation and institutional traceability require a project-level specification.
In those cases, adding a near-neighbor catalog SKU to a cart does not close the gap. It creates a material that will be hard to defend in the notebook. The correct move is a written scope. That pathway is documented on custom peptide design and synthesis for laboratories.
Qualification before synthesis
Custom work should not start as an open-ended promise. Simple Life Sciences treats RFQ and custom synthesis as technical review covering sequence or structure, scale, purity targets, analytics, and written quotation — not impulse cart adds.
Qualification, in the sense used on the quality page, begins with provenance and the documents a lot will need. For a custom peptide, that idea moves upstream: the laboratory requirement itself must be qualified before anyone synthesizes.
Ask whether the intended use is clearly non-clinical laboratory research; whether the sequence or target concept is specified enough to review feasibility (length, difficult motifs, solubility risk, termini, modifications); which analytical methods will count as identity and purity for this project; what presentation and lot documentation must ship with the material; and whether destination or third-party-rights constraints belong in review.
Not every request is accepted automatically. About Simple Life Science notes that feasibility, specification, intended non-clinical use, destination, documentation, and applicable third-party rights remain part of technical and commercial review. That is a feature of a laboratory supplier, not a delay tactic.
The written-scope pathway
The custom hub describes a four-stage pathway. Treat it as a project record, not as marketing steps.
1. Intake. Capture sequence or target concept, scale, modifications, purity, format, analytics, and intended non-clinical research use. Incomplete intake produces unquoted assumptions. If the lab does not yet have a final sequence, say so; a feasibility review is different from a synthesis kickoff.
2. Written scope. Confirm feasibility, assumptions, specifications, methods, packaging, timeline, and commercial terms in a written project record. This is the document both sides should be able to retrieve later. Verbal “can you make this?” is not a scope.
3. Synthesis and purification. Execute the accepted plan against the defined specification and milestones. Changes to sequence, scale, or purification target after acceptance should go back through the written record rather than through chat.
4. Analytics and closeout. Complete agreed identity/purity methods, package the material, and issue project documentation for laboratory receipt. Closeout is part of the material. A vial without the agreed records is an incomplete delivery.
Capability statements remain subject to technical feasibility, Quality review, and an accepted written scope. This article does not invent yields, purity percentages, or patent claim charts. Where intellectual-property status is mentioned at all, it stays at a high level (for example patent pending as a public status) and never as a claim chart.
What to put in a laboratory RFQ
A usable RFQ is specific and still RUO-safe. Include organization, receiving site, and scientific contact; sequence (or a clearly labeled target concept if the sequence is not final); termini, modifications, labels, and known liabilities; approximate scale as a requirement, not as a published price break; purification / purity target as a specification the lab needs, with the understanding that the released lot result and method will control; requested analytics (for example RP-HPLC method context and mass identity support); presentation and packaging; intended non-clinical research use in one or two sentences — enough for use-case control, not a protocol for administration; and documentation expected at closeout (COA, method notes, specification, handling).
Send that package through the custom peptide synthesis project record or institutional quotation form described on the custom synthesis hub. Do not treat a catalog search box as an RFQ.
Analytics and documentation as part of the delivery
Custom synthesis fails as procurement when the lab receives powder and an invoice. It succeeds when the closeout pack can be archived next to the lot.
Align custom documentation with the same rules used for catalog lots. Identity, purity method, lot or project identifier, and release or closeout status should be present. Purity statements name the method and defer to the released result and any molecule-specific specification. Public copy never replaces the lot or project COA. See the FAQ language collected on the custom and documentation library pages.
Quality systems still apply: qualify, review, verify, release. Custom work does not skip incoming review just because the sequence was requested by the buyer. If a current record is missing at receipt, request it with project or catalog reference, lot, organization, and document type rather than substituting a catalog example from an unrelated SKU.
Enterprise names in search vs a documentation-first RFQ
Rising interest around custom peptide synthesis often surfaces large enterprise catalog and CRO names — for example GenScript- and Thermo Fisher–class results — alongside job boards and price curiosity. Those names signal search landscape, not a requirement to copy their storefront model.
A documentation-first boutique RFQ answers a different question: can this laboratory write a scope (sequence, scale, purity target, analytics, presentation, closeout pack) and receive a lot or project record that archives next to the material? Enterprise brand familiarity is not a substitute for that written scope. Compare documentation posture and feasibility review — not logo size. See custom peptide synthesis for the intake → written scope → synthesis → analytics/closeout pathway.
“Price” in search is not a price list
When Trends surfaces “price” next to custom peptide synthesis, buyers are usually estimating scope cost — not asking a supplier to publish a public menu. Sequence length, difficult motifs, modifications, purification target, analytical package, presentation, turnaround, and documentation pack all move the quotation. Publishing a flat price list would mis-teach that reality.
Treat price curiosity as a prompt to complete the RFQ variables above. The controlling commercial document remains the written quotation against an accepted scope — never a screenshot of someone else’s catalog card. Quality still governs: quality systems apply whether the material is stock or custom.
What custom synthesis does not mean
Custom peptide design for laboratories does not mean a clinical, compounding, or consumer product pathway; dosing, injection, or administration guidance; a promise that any sequence can be made at any purity; a price list, discount code, or catalog cannibalization pitch toward another brand’s SKUs; or a substitute for the lab’s own feasibility, safety, and documentation practices.
Research use only is a boundary, not a disclaimer buried under a checkout button. Why Simple Life Sciences keeps catalog language and related destinations framed for laboratory research. Custom projects inherit that frame.
Simple Life Science is the life-science and laboratory-research sister brand to Simple Peptide — same operators and quality posture, positioned for institutions and labs that need lot-level documentation, bulk API, and custom synthesis under clear RUO boundaries. It extends that experience; it does not ask buyers to “shop here instead” for the same catalog SKUs. Entity context lives on About.
Start with scope, then quality
If a catalog presentation cannot carry the experiment, do not force it. Open a written scope on custom peptide synthesis, and read it against the quality and documentation model before any synthesis begins. Retrieve example lot documentation from the documentation library (also the COA library) when you need to see how identity, method, and release are typically recorded — without treating that index as a store.
The laboratory requirement is the specification. Custom synthesis is how that specification becomes a documented material. Everything else is a catalog approximation.